These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31227501)

  • 1. Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.
    Matikas A; Zerdes I; Lövrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
    Clin Cancer Res; 2019 Sep; 25(18):5717-5726. PubMed ID: 31227501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
    Zhang M; Sun H; Zhao S; Wang Y; Pu H; Wang Y; Zhang Q
    Oncotarget; 2017 May; 8(19):31347-31354. PubMed ID: 28430626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
    Huang W; Ran R; Shao B; Li H
    Breast Cancer Res Treat; 2019 Nov; 178(1):17-33. PubMed ID: 31359214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of programmed death ligand 1 expression in resected lung adenocarcinoma: a systematic review and meta-analysis.
    Chen D; Mao Y; Ding Q; Wang W; Zhu F; Chen C; Chen Y
    Eur J Cardiothorac Surg; 2020 Nov; 58(5):888-898. PubMed ID: 32596715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
    Li S; Chen L; Jiang J
    Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
    Wang L
    J Ovarian Res; 2019 Apr; 12(1):37. PubMed ID: 31039792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
    Kim HM; Lee J; Koo JS
    BMC Cancer; 2017 Oct; 17(1):690. PubMed ID: 29041905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
    Wang Q; Liu F; Liu L
    Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis.
    Zhang Y; Tian J; Qu C; Tang Z; Wang Y; Li K; Yang Y; Liu S
    Medicine (Baltimore); 2020 Dec; 99(49):e23359. PubMed ID: 33285715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.
    Muenst S; Schaerli AR; Gao F; Däster S; Trella E; Droeser RA; Muraro MG; Zajac P; Zanetti R; Gillanders WE; Weber WP; Soysal SD
    Breast Cancer Res Treat; 2014 Jul; 146(1):15-24. PubMed ID: 24842267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.
    Li J; Wang P; Xu Y
    PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis.
    Boman C; Zerdes I; Mårtensson K; Bergh J; Foukakis T; Valachis A; Matikas A
    Cancer Treat Rev; 2021 Sep; 99():102257. PubMed ID: 34237488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer.
    Zhai Q; Fan J; Lin Q; Liu X; Li J; Hong R; Wang S
    PLoS One; 2019; 14(10):e0223325. PubMed ID: 31584964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.
    Zhang M; Li G; Wang Y; Wang Y; Zhao S; Haihong P; Zhao H; Wang Y
    Sci Rep; 2017 Aug; 7(1):10255. PubMed ID: 28860576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count.
    Miyama Y; Morikawa T; Miyakawa J; Koyama Y; Kawai T; Kume H; Fukayama M
    Cancer Med; 2018 Sep; 7(9):4330-4338. PubMed ID: 30062756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
    Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
    Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
    Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.